Monday, January 30, 2023
198 Nigeria News
No Result
View All Result
  • HOME
  • VIDEO NEWS
  • BUSINESS NEWS
  • FEATURED NEWS
    • NIGERIA USA NEWS
    • NIGERIA EU NEWS
    • NIGERIA CHINA NEWS
    • NIGERIA UK NEWS
    • NIGERIA FRANCE NEWS
    • NIGERIA GULF NATIONS NEWS
    • NIGERIA INDIA NEWS
    • NIGERIA RUSSIA NEWS
    • NIGERIA ITALY NEWS
    • NIGERIA TURKEY NEWS
    • NIGERIA EGYPT NEWS
    • NIGERIA BRAZIL NEWS
    • NIGERIA THAILAND NEWS
    • NIGERIA PHILIPPINE NEWS
  • POLITICAL NEWS
  • MORE NEWS
    • NIGERIA TECHNOLOGY NEWS
    • NIGERIA MOVIE INDUSTRY
    • NIGERIA CRYPTO NEWS
    • NIGERIA AGRICULTURE NEWS
    • OVERSEAS JOBS NEWS
    • NIGERIA CONSTRUCTION NEWS
    • OVERSEAS SPONSORSHIP
    • 198TILG MEDIA TRAINING
    • NIGERIA IMMIGRATION NEWS
    • NIGERIA EDUCATION NEWS
    • NIGERIA VENTURE CAPITAL NEWS
    • NIGERIA JOINT VENTURE NEWS
    • NIGERIA UNIVERSITIES
    • NIGERIA MANUFACTURERS
    • NIGERIA BUSINESS HELP
    • NIGERIA PARTNERSHIP
  • ASK IKE LEWUMA
  • REGISTER NGO
  • CONTACT
  • HOME
  • VIDEO NEWS
  • BUSINESS NEWS
  • FEATURED NEWS
    • NIGERIA USA NEWS
    • NIGERIA EU NEWS
    • NIGERIA CHINA NEWS
    • NIGERIA UK NEWS
    • NIGERIA FRANCE NEWS
    • NIGERIA GULF NATIONS NEWS
    • NIGERIA INDIA NEWS
    • NIGERIA RUSSIA NEWS
    • NIGERIA ITALY NEWS
    • NIGERIA TURKEY NEWS
    • NIGERIA EGYPT NEWS
    • NIGERIA BRAZIL NEWS
    • NIGERIA THAILAND NEWS
    • NIGERIA PHILIPPINE NEWS
  • POLITICAL NEWS
  • MORE NEWS
    • NIGERIA TECHNOLOGY NEWS
    • NIGERIA MOVIE INDUSTRY
    • NIGERIA CRYPTO NEWS
    • NIGERIA AGRICULTURE NEWS
    • OVERSEAS JOBS NEWS
    • NIGERIA CONSTRUCTION NEWS
    • OVERSEAS SPONSORSHIP
    • 198TILG MEDIA TRAINING
    • NIGERIA IMMIGRATION NEWS
    • NIGERIA EDUCATION NEWS
    • NIGERIA VENTURE CAPITAL NEWS
    • NIGERIA JOINT VENTURE NEWS
    • NIGERIA UNIVERSITIES
    • NIGERIA MANUFACTURERS
    • NIGERIA BUSINESS HELP
    • NIGERIA PARTNERSHIP
  • ASK IKE LEWUMA
  • REGISTER NGO
  • CONTACT
No Result
View All Result
198 Nigeria News
No Result
View All Result
Home NIGERIA INDIA NEWS

Africa: Patients Across Four Continents Enrol in Multidrug-Resistant Tuberculosis Trial

198 Nigeria News by 198 Nigeria News
October 19, 2021
in NIGERIA INDIA NEWS
0
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

[ad_1]

Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Médecins Sans Frontières (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD) make up the endTB consortium conducting the groundbreaking study funded by Unitaid.

Started in 2017, this phase III randomised, controlled trial recruited 750 patients with MDR-TB across seven countries: Georgia, India, Kazakhstan, Lesotho, Pakistan, Peru, and South Africa. The trial compares five new treatment regimens for treating MDR-TB containing two of the three new TB drugs developed in recent years, bedaquiline and delamanid, in combination with other existing oral TB drugs. This new generation of drugs, which were developed after a nearly 50-year drought in new anti-TB drug classes, now allows for the development of radically shorter (6 or 9 months versus as long as two years), more tolerable, injection-free treatments for MDR-TB.

“An old enemy of mankind, tuberculosis remains the deadliest infectious disease today. And MDR-TB is the most cruel and merciless version,” says Dr Lorenzo Guglielmetti, endTB Project Leader for MSF and co-principal investigator of the trial. “The coming results of this trial could be lifechanging for more than 500,000 people suffering from MDR-TB, and may help to appropriately treat millions of patients, tomorrow and in decades to come.”

With sobering new data showing progress against TB slipping backwards for the first time in over a decade, new tools and treatments are more crucial than ever. Dr Philippe Duneton, Executive Director of Unitaid

The results, which will be available in 2023, will be relevant to a wide range of patients living with MDR-TB. This is because of the diversity in the study population: while all patients were sick with TB resistant to standard treatment, the study population included people from a range of racial and ethnic backgrounds. It also included people affected by comorbidities that occur commonly with MDR-TB like HIV, hepatitis C or diabetes. People with these conditions are often excluded from TB trials making it difficult for doctors to know how best to treat their patients.

“With sobering new data from the Global TB Report showing progress against TB slipping backwards for the first time in over a decade, new tools and treatments are more crucial than ever,” said Dr Philippe Duneton, Executive Director of Unitaid. “The innovative multi-country endTB trial will benefit not only people with MDR-TB – a more complex and difficult to cure strain of TB – but it is also building long-term capacity in the countries that are managing this multi-faceted clinical trial.”

Other reasons explain why this trial stands out.

First, the trial is innovative. Regulatory bodies had approved the individual medications – the first new drugs for tuberculosis in 50 years – but how to optimally combine these drugs was unknown. Rather than testing different drug regimens sequentially over a decade or longer, partners applied adaptive randomisation, maximising the number of patients who get well performing experimental regimens. This allows for a relatively small sample size (750), requires fewer resources, and may enable dramatic improvements in treatment over short periods of time.

Second, enrolment is designed to benefit all. endTB enrolled women and adolescents – groups that are often left out of clinical trials in an effort to protect them – to be sure that doctors have the data they need to best to care for them. The consortium helped train staff at clinical sites, thus enabling more research, faster recommendations, and better treatments in the future.

Lastly, it’s significant that enrolment was completed despite massive constraints related to the COVID-19 pandemic. The COVID-19 pandemic has paused hundreds of clinical trials. Universities, hospitals, labs, and others have been forced to stall or cancel research into illnesses ranging from cancer to rare diseases. Instead, the endTB consortium adapted and continued.

Sign up for free AllAfrica Newsletters

Get the latest in African news delivered straight to your inbox


Success!

Almost finished…

We need to confirm your email address.

To complete the process, please follow the instructions in the email we just sent you.


Error!

There was a problem processing your submission. Please try again later.

This clinical trial is part of the larger endTB project that was launched to revolutionise treatment for MDR-TB patients. Approximately 2,800 patients from 17 countries were enrolled in an observational study that produced strong evidence of the effectiveness of new drugs (85 per cent culture conversion in the first six months of treatment) and further supports a rapid increase in access to these drugs. A second randomised controlled trial, called endTB-Q, is underway to study a 6-9 month regimen to treat the most resistant form of MDR-TB.

In addition, the endTB trial complements the TB-PRACTECAL clinical trial, also sponsored by MSF, which include another newer drug called pretomanid to provide high-quality evidence on shorter, all-oral regimens. Ultimately, both trials address the critical need for increased treatment options – and access – for the approximately 500,000 people who fall sick each year with MDR-TB.

[ad_2]

Source link

Tags: AfricaContinentsEnrolMultidrugResistantPatientsTrialTuberculosis
198 Nigeria News

Nigeria Smart News contributes to latest news of Nigeria Smart news and Up to date with technology news.

198massmedia Group. USA. 3821 Dominion Drive, Dumfries, USA. 22026.

Toll Free 1 888 642 8433.
Contact: info@198nigerianews.com

LATEST UPDATES

Ghanaian, Dutch Businesses to Explore Business Opportunities

Macron heads to Cameroon for 3-nation Africa tour amid mixed reception

Africa Taken for Neo-Colonial Ride — Global Issues

Kenya: Visa Processing Delays a Result of Backlog Caused By Covid-19 Pandemic – U.S. Embassy

Africa: Over 10 Million Covid-19 Recoveries Confirmed Across Continent

Both UK & Congo Think They’re Climate Leaders COP26s Fallout Shows How Far Adrift They Are — Global Issues

Trump returns to Washington after 2020 election loss

Africa: Russia Turns to Africa Amid Diplomatic Isolation

Terrorists attack Nigerias Presidential Guards Brigade, wound 3 soldiers

RECOMMENDED

No Content Available
  • Home
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2022 - 198 Nigeria News.

No Result
View All Result
  • HOME
  • VIDEO NEWS
  • BUSINESS NEWS
  • FEATURED NEWS
    • NIGERIA USA NEWS
    • NIGERIA EU NEWS
    • NIGERIA CHINA NEWS
    • NIGERIA UK NEWS
    • NIGERIA FRANCE NEWS
    • NIGERIA GULF NATIONS NEWS
    • NIGERIA INDIA NEWS
    • NIGERIA RUSSIA NEWS
    • NIGERIA ITALY NEWS
    • NIGERIA TURKEY NEWS
    • NIGERIA EGYPT NEWS
    • NIGERIA BRAZIL NEWS
    • NIGERIA THAILAND NEWS
    • NIGERIA PHILIPPINE NEWS
  • POLITICAL NEWS
  • MORE NEWS
    • NIGERIA TECHNOLOGY NEWS
    • NIGERIA MOVIE INDUSTRY
    • NIGERIA CRYPTO NEWS
    • NIGERIA AGRICULTURE NEWS
    • OVERSEAS JOBS NEWS
    • NIGERIA CONSTRUCTION NEWS
    • OVERSEAS SPONSORSHIP
    • 198TILG MEDIA TRAINING
    • NIGERIA IMMIGRATION NEWS
    • NIGERIA EDUCATION NEWS
    • NIGERIA VENTURE CAPITAL NEWS
    • NIGERIA JOINT VENTURE NEWS
    • NIGERIA UNIVERSITIES
    • NIGERIA MANUFACTURERS
    • NIGERIA BUSINESS HELP
    • NIGERIA PARTNERSHIP
  • ASK IKE LEWUMA
  • REGISTER NGO
  • CONTACT

Copyright © 2022 - 198 Nigeria News.